EP1124845A2 - Phosphinat-peptidanaloga zur behandlung von fibrotischen erkrankungen - Google Patents
Phosphinat-peptidanaloga zur behandlung von fibrotischen erkrankungenInfo
- Publication number
- EP1124845A2 EP1124845A2 EP99969897A EP99969897A EP1124845A2 EP 1124845 A2 EP1124845 A2 EP 1124845A2 EP 99969897 A EP99969897 A EP 99969897A EP 99969897 A EP99969897 A EP 99969897A EP 1124845 A2 EP1124845 A2 EP 1124845A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- pcp
- acid
- astacin
- phosphinate
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- Phosphinate peptide analogues for the treatment of fibrotic diseases are Phosphinate peptide analogues for the treatment of fibrotic diseases.
- the invention relates to the use of phosphinate peptide analogs as inhibitors of procollagen C proteinase (PCP) for the treatment of fibrotic diseases.
- PCP procollagen C proteinase
- PCP Procollagen C proteinase
- PCP is probably also responsible for the hydrolytic cleavage of the propeptide sequence of the lysyl oxidase.
- the cleavage of the prosequence probably leads to the activation of the catalytic lysyl oxidase activity of the matures
- PCP-like proteases can release TGFß-like growth factors from an inactive complex with TGFß binding proteins [cf. Marques G, Musacchio M, Shimell MJ, Wünnenberg-Stapleton K, Cho KWY, O'Connor MB: Production of a DPP activity gradient in the early drosophila embryo through the opposing actions of the SOG and TLD proteins, Cell 91: 417-426 (1997);
- TGFß-like growth factors The binding partner of the TGFß-like growth factors is decomposed by specific proteolysis.
- the PCP may also have a TGFß agonistic activity. Therefore, the PCP can be assigned a crucial role in fibrogenesis.
- the PCP activity is due to splicing variants of the BMP-I gene [cf. Kessler E, Takahara K, Biniaminow L, Brusel M, Greenspan DS: Bone morphogenetic protein-1: The type I procollagen C-proteinase, Science 271: 360-362 (1996)); Reddi AH:
- BMP-1 Resurrection as procollagen C proteinase. Science 217: 463 (1996); Li SW, Sieron AL, Fertala A, Hojima Y, Arnold WV, Prockop DJ: The C-proteinase that processes procollagens to fibrillar collagens is identical to the protein previosly identified as bone-morphogenetic protein- 1. Proc. Natl. Acad. Be. USA 93: 5127-5130 (1996)]. So far it has been ensured that the splice variants BMP I-I and BMP I-III
- PCP belongs to the family of astacin proteases.
- the crystal structure of Astacin is known in detail.
- R 1 represents hydrogen or methyl
- Physiologically acceptable salts are preferred in the context of the invention.
- Physiologically acceptable salts are generally salts of the compounds according to the invention with inorganic or organic acids. Salts with inorganic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid, or salts with organic carboxylic or sulfonic acids, such as acetic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid, are preferred. acid, or methanesulfonic acid, ethanesulfonic acid, phenylsulfonic acid, toluenesulfonic acid or naphthalenedisulfonic acid.
- the compounds according to the invention can exist in stereoisomeric forms which either behave like image and mirror image (enantiomers) or do not behave like image and mirror image (diastereomers).
- the invention relates to both the antipodes and the racemic forms as well as the diastereomer mixtures.
- the compounds of the general formula (I) can exist in all enantiomeric and diastereomeric forms.
- Preferred isomers are those in which the parts of the molecule formed from proline, lysine and leucine have the L configuration, as well as their salts and prodrugs.
- Phosphinate peptide analogs of the general formula (I) with the configuration shown are particularly preferred
- R 1 represents hydrogen or methyl
- the compound of the general formula (Ib) is very particularly preferred
- the compounds of the general formula (I) are known and can in principle be prepared from corresponding phosphinate compounds by customary methods of peptide synthesis [cf. see Yiotakis A, Vassilio S, Jiracek J, Dive V: Protection of the Hydroxyphosphinyl Function of Phosphinic Dipeptides by Adamantyl. Application to the Solid-Phase Synthesis of Phosphinic Peptides, J. Org. Chem. 61: 6601-6605 (1996); Campagne JM, Coste J, Guillou L, Heitz A, Jouin P: Solid phase synthesis of phosphinic peptides, Tetrahedron Lett. 34: 4181-4184
- Meprin I ⁇ IG-Q
- This loop forms the essential part of the Sl 'binding pocket of the astacin-like proteases.
- astacin and meprin lies the key to the different substrate and inhibitor specificity of both enzymes.
- Meprin and Astacin differ very clearly in the Sl 'pocket.
- the PCP also has two proline residues and one lysine residue in this region. How through
- the compounds according to the invention are distinguished by a very high potency in inhibiting PCP.
- the compounds according to the invention are therefore suitable for the treatment of liver fibrosis of any genesis and fibrosis with a different organ manifestation.
- liver fibrosis of different origins, such as e.g. alcoholic cirrhosis of the liver, biliary cirrhosis, hepatitis viral or other genesis, idiopathic interstitial fibrosis, idiopathic pulmonary fibrosis, acute pulmonary
- Fibrosis the acute respiratory distress syndrome (ARDS), perimuscular fibro- sen, pericentral fibrosis, dermatofibromas, renal fibrosis, diabetic nephropathy, glomerulonephritis, systemic or local scleroderma, keloids, hypertrophic scarring, joint adhesions, arthrosis, myelofibrosis, scarring of the cornea, muscular fibrosis, the cystic fibrosis, the cystic fibrosis, the cystic fibrosis muscular dystrophy, esophageal stricture, 'Ormond's disease,
- the invention also includes fibrotic diseases which are initiated or caused by surgical scar revisions, plastic surgery, glaucoma, cataract fibrosis, scarring of the cornea, the so-called "graft versus host disease", surgical interventions on tendons, nerve pinching syndromes, the Dupuytren's contracture , Adhesions due to gynecological interventions, pelvic adhesions, peridural fibrosis, diseases of the thyroid or parathyroid glands, due to metastatic bone infestation, multiple myeloma or restenosis.
- a synthetic decapeptide substrate with the sequence was used to detect the PCP activity
- This peptide frequency corresponds to the region in the
- Procollagen ⁇ 2 (I) which is cleaved by PCP.
- the fission sequence is known to biochemical experts [cf. Lee ST, Kessler E, Greenspan DS: Analysis of site-directed mutations in human pro- ⁇ 2 (I) collagen which block cleavage by the C-proteinase, J. Biol. Chem. 265: 21992-21996 (1990)] as well the procedure of the dequench test [cf. Matayoshi ED, Wang GT, Krafft GA, Erickson J: Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer, Science 247: 954-958 (1989)].
- the concentration of the synthetic peptide was 5.6 ⁇ M, the final buffer conditions were: 50 mM Tris pH 7.5, 150 mM NaCl and 0.005% Br ' ij35.
- the kinetic test was carried out as described below: The fluorescent substrate was dissolved in 90 ⁇ l reaction buffer. The kinetics of substrate turnover by PCP was detected in duplicate by fluorescence measurement (Ex. 355 nm / Em. 538 nm) between 0 to 120 min. The reaction was through
- the relative substrate turnover in% of the total amount was calculated from:
- Ft is the relative fluorescence after a time interval t under incubation with PCP.
- Ft is the corresponding relative fluorescence after the time interval t without PCP addition
- Ftotal is the fluorescence after total hydrolysis by adding proteinase K
- Fini is the initial relative fluorescence before the start of the reaction by adding proteinase K.
- the PCP activity used was typically adjusted so that approximately 20% of the substrate was reacted with the inhibited enzyme within the measurement period.
- Figure 1 is a typical reaction kinetics (% conversion) 'with the addition of
- Phosphinate inhibitors Z- PKF (PC) APL-O-Me Phosphinate inhibitors Z- PKF (PC) APL-O-Me.
- Figure 2 shows the concentration-activity relationship of a phosphinate inhibitor.
- Meprin is an enzyme from the family of astacin proteases that occurs in humans (Stöcker W, Gomis-Rüth FX, Bode W, Zwilling R: Implications of the three-dimensional structure of astacin for the structure and function of the astacin family of zinc- endopeptidases, Eur. J. Biochem. 214: 215-231 (1993)).
- the __- meprine activity test was carried out completely analogously to the in vitro assay for measuring the PCP activity. Instead of the recombinant PCP, human meprin was used, which also converts the fluorescence-labeled decapeptide.
- Figure 3 shows the specificity of the highly effective phosphinate peptide analog Z - PKF (PC) APL - O-Me for PCP. Even at concentrations up to 100 nM (dose-dependent), Meprin is only insignificantly inhibited during the conversion of the fluorescence-labeled peptide. Demonstration of biological effectiveness
- liver fibrosis by bile duct ligation [cf. Kountouras J, Billing B, Scheuer P: Prolonged bile obstruction: a new experimental model for cirrhosis in the rat, Br. J. Exp. Pathol. 1984; 65: 305-311 (1984)] or the liver fibrosis induced by heterologous serum [cf. Bhunchet E, Wake K .: Suppression of experimental hepatic fibrosis by administration of vitamin A, Lab. Invest. 1985; 52: 182-194 (1985)] can be used.
- Other animal models with liver fibrosis can also be used to demonstrate the antifibrotic effect.
- animal models can also be used for other fibrosis mam stations, for example in the heart, kidneys, lungs, skin or other organs.
- the reduction in collagen deposition can be determined, for example, by determining the hydroxyproline content [cf. Gerling B, Becker M, Waldschmidt J, Rehmann M, Schuppan D .: Elevated serum amino terminal procollagen type-III-peptide parallels collagen accumulation in rats with secondary biliary fibrosis, Hepatology 1996; 25: 79-84 (1996)] of the fibrotic organs or by quantitative morphometry [cf.
- Figure 1 shows the substrate turnover of the DABCYL-EDANS decapeptide by recombinant PCP as a function of time. The enzyme activity is almost completely inhibited in the presence of 100 nM inhibitor.
- Figure 2 shows the concentration-activity relationship of the phosphinate inhibitor
- Figure 3 shows the specificity of the highly effective phosphinate peptide analog Z - PKF (PC) APL - O-Me for PCP. Even at concentrations up to 100 nM (dose-dependent), Meprin is only insignificant in the implementation of the fluorescence-labeled
- the present invention also includes pharmaceutical preparations which, in addition to inert, non-toxic, pharmaceutically suitable auxiliaries and excipients, contain one or more compounds of the general formula (I) or which consist of one or more active compounds of the formulas (I), and processes for the preparation of these preparations.
- the active compounds of the formulas (I) should be present in these preparations in a concentration of 0.1 to 99.5% by weight, preferably 0.5 to 95% by weight, of the total mixture.
- the pharmaceutical preparations can also contain other pharmaceutical active ingredients.
- the pharmaceutical preparations listed above can be prepared in a customary manner by known methods, for example using the excipient or excipients.
- the active compound (s) in a total amount of about 0.01 to about 100 mg / kg, preferably in total amounts of about 1 mg / kg to 50 mg / kg body weight per 24 hours , if necessary in the form of several single doses, to achieve the desired result.
- Example la The protected amine derivative from Example la is dissolved in ethanol (approx. 0.05 mol / 1) and a catalyst (10% palladium on carbon) is added under argon. The suspension is approx. 2 at room temperature under H 2 atmosphere (normal pressure)
- Example lc The protected amine derivative from Example lc is dissolved in ethanol (approx. 0.05 mol / 1) and a catalyst (10% palladium on carbon) is added under argon. The suspension is approx. 2 at room temperature under H 2 atmosphere (normal pressure)
- Example le (1 R) - 1 - ( ⁇ (2S) -2- amino-6 - [(tert-butoxycarbonyl) amino] hexanoyl ⁇ - amino) -2-phenylethy 1 ⁇ 3 - [(2S) - 2- ( ⁇ [(15) - 1 - (methoxycarbony l) -3 - methylbutyl] amino ⁇ carbony l) tetrahydro-1 H-pyrrole-1-yl] -2-methyl-3-oxopropyl ⁇ phosphinic acid
- 0.3 ml of trifluoroacetic acid is added dropwise to 24.50 mg (0.03 mmol) of the compound from Example le in an ice-cooled mixture of 0.3 ml of methylene chloride and 0.03 ml of water. The cooling is removed and the mixture is stirred at room temperature for two hours before being concentrated in vacuo and dried thoroughly in a high vacuum.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19850072 | 1998-10-30 | ||
DE19850072A DE19850072A1 (de) | 1998-10-30 | 1998-10-30 | Phosphinat-Peptidanaloga zur Behandlung von fibrotischen Erkrankungen |
PCT/EP1999/008181 WO2000027377A2 (de) | 1998-10-30 | 1999-10-28 | Phosphinat-peptidanaloga zur behandlung von fibrotischen erkrankungen |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1124845A2 true EP1124845A2 (de) | 2001-08-22 |
Family
ID=7886165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99969897A Withdrawn EP1124845A2 (de) | 1998-10-30 | 1999-10-28 | Phosphinat-peptidanaloga zur behandlung von fibrotischen erkrankungen |
Country Status (7)
Country | Link |
---|---|
US (1) | US6750202B1 (de) |
EP (1) | EP1124845A2 (de) |
JP (1) | JP2002529403A (de) |
AU (1) | AU3148100A (de) |
CA (1) | CA2348934A1 (de) |
DE (1) | DE19850072A1 (de) |
WO (1) | WO2000027377A2 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10053870A1 (de) * | 2000-10-31 | 2002-05-08 | Burchardt Elmar Reinhold | Procollagen (III)-Propeptide und verwandte Substanzen zur Behandlung von fibrotischen Erkrankungen |
DE10134243A1 (de) * | 2001-07-14 | 2003-03-27 | Burchardt Elmar Reinhold | Phosphimat-Peptidanalyse zur Behandlung von fibrotischen Erkrankungen |
AU2015205370B2 (en) * | 2014-01-10 | 2017-11-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Hydroxy formamide derivatives and their use |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3539736B2 (ja) * | 1996-08-28 | 2004-07-07 | ザ プロクター アンド ギャンブル カンパニー | 基質メタロプロテアーゼインヒビターとしてのホスフィン酸アミド |
US6008017A (en) | 1997-01-02 | 1999-12-28 | Smithkline Beecham Corporation | Human cardiac/brain tolloid-like protein |
-
1998
- 1998-10-30 DE DE19850072A patent/DE19850072A1/de not_active Withdrawn
-
1999
- 1999-10-28 US US09/830,741 patent/US6750202B1/en not_active Expired - Fee Related
- 1999-10-28 EP EP99969897A patent/EP1124845A2/de not_active Withdrawn
- 1999-10-28 CA CA002348934A patent/CA2348934A1/en not_active Abandoned
- 1999-10-28 JP JP2000580606A patent/JP2002529403A/ja active Pending
- 1999-10-28 AU AU31481/00A patent/AU3148100A/en not_active Abandoned
- 1999-10-28 WO PCT/EP1999/008181 patent/WO2000027377A2/de active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of WO0027377A2 * |
Also Published As
Publication number | Publication date |
---|---|
CA2348934A1 (en) | 2000-05-18 |
JP2002529403A (ja) | 2002-09-10 |
DE19850072A1 (de) | 2000-05-04 |
WO2000027377A3 (de) | 2000-11-16 |
US6750202B1 (en) | 2004-06-15 |
AU3148100A (en) | 2000-05-29 |
WO2000027377A2 (de) | 2000-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69325178T2 (de) | Durch peptidylketon aktivierte inhibitoren, die natürliche und nicht-natürliche peptidsequenzen enthalten | |
DE69030315T2 (de) | Kleine zyklische inhibitoren der blutplättchenaggregation | |
JPH11511137A (ja) | コラーゲンの過剰生産に関係した疾患を治療するためのc−プロテイナーゼ阻害剤 | |
US5486623A (en) | Cysteine protease inhibitors containing heterocyclic leaving groups | |
DE69225426T2 (de) | Neue Thrombin-Inhibitoren | |
DE69725354T2 (de) | Intermediate zur Herstellung von Thrombininhibitoren als Anticoagulantien | |
JPH09500087A (ja) | カルパイン活性の増大に関連した健康障害の抑制及び処置におけるカルパイン阻害剤の使用法 | |
US5672583A (en) | Carboxy-peptidyl derivatives as antidegenerative active agents | |
DE69507062T2 (de) | Verbindungen zur Hemmung der Thrombin | |
DE69520056T2 (de) | Verbindungen zur Hemmung von Thrombin | |
DE602004012777T2 (de) | 2-hydroxytetrahydrofuranderivate und ihre verwendung als arzneimittel | |
US5679700A (en) | Substituted phosphinic acid-containing peptidyl derivatives as antidegenerative agents | |
EP1272458A1 (de) | Arginin-mimetika als faktor xa-inhibitoren | |
US5403952A (en) | Substituted cyclic derivatives as novel antidegenerative agents | |
DE69625230T2 (de) | Thrombininhibitoren | |
DE69818698T2 (de) | Inhibitoren von metalloproteinasen, ihre therapeutische verwendung und verfahren zur herstellung der grundstoffe für ihre synthese | |
DE2809036C2 (de) | Trans-Epoxybernsteinsäurederivate | |
EP1124845A2 (de) | Phosphinat-peptidanaloga zur behandlung von fibrotischen erkrankungen | |
EP1483285B1 (de) | HEMMSTOFFE DES GERINNUNGSFAKTORS Xa, IHRE HERSTELLUNG UND VERWENDUNG | |
EP1455808B1 (de) | Phosphinat-peptidanaloga als inhibitoren der procollagen-c-proteinase (pcp) zur behandlung von fibrotischen erkrankungen | |
US6090785A (en) | Substituted N-carboxyalkylpeptidyl derivatives as antidegenerative agents | |
DE69908756T2 (de) | Matrix-metalloproteinase-inhibitoren | |
WO1994027958A1 (de) | 4-amidinophenylsulfonamide zur behandlung von thromboembolischen erkrankungen | |
DE60036087T2 (de) | Niedermolekulare peptidderivate als inhibitoren der laminin/nidogen wechselwirkung | |
JP2003502442A (ja) | セリンエラスターゼの活性を阻害する方法及び化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010530 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BURCHARDT, ELMAR REINHOLD, DR. DR. |
|
RBV | Designated contracting states (corrected) |
Designated state(s): DE ES FR GB IT |
|
17Q | First examination report despatched |
Effective date: 20070417 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 38/05 20060101AFI20071102BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080404 |